53 results
8-K
EX-1.1
MREO
Mereo Biopharma Group Plc
14 Jun 24
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
4:30pm
or similar assessment, fine or penalty levied against any of them, except (i) as are being contested in good faith and as to which adequate reserves have
8-K
EX-5.1
MREO
Mereo Biopharma Group Plc
14 Jun 24
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
4:30pm
omitted from it; and
we have not undertaken any consideration, analysis or assessment of whether the National Security & Investment Act 2021 (“NS&IA
S-3
EX-5.1
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
consideration, analysis or assessment of whether the National Security & Investment Act 2021 (“NS&IA”) may or will apply to any of the transactions
S-3
EX-1.2
MREO
Mereo Biopharma Group Plc
15 May 24
Shelf registration
4:49pm
assessment, fine or penalty levied against any of them, except (i) as are being contested in good faith and as to which adequate reserves have been
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
15 May 24
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:06pm
and is suitable for use as a key Clinical Outcomes Assessment endpoint.
The global Phase 3 study, which is supported by positive data from the ASTRAEUS
DEF 14A
79w4of4
24 Apr 24
Definitive proxy
7:30am
10-K
1i5qv0tk02tw
27 Mar 24
Annual report
5:20pm
10-K
EX-10.30
un5vk8nbcwymo1i jr
27 Mar 24
Annual report
5:20pm
8-K
EX-99.1
57q55z6uktr08ge
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
S-8
EX-4.3
c1ihz07oby
23 Jan 24
Registration of securities for employees
4:16pm
8-K
EX-99.1
7ujvk72xpa26
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
6-K
EX-99.1
vyjn8114
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
EX-99.2
e08wpry5sjmxlg4j328u
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
yast6f1fbep6t4uarb
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
38hbpif9md1sc8 7fl
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
ysx36q6
9 May 22
Current report (foreign)
8:06am
6-K
vc1 12r72h5il4
9 May 22
Current report (foreign)
8:06am
6-K
EX-99.1
s5fezop0eqcj
22 Dec 21
Alvelestat reported safe and well-tolerated in patients with COVID-19
7:45am